Patents Assigned to Eisai R&D Management Co., Ltd.
  • Pentacyclic heterocycles
    Patent number: 11358972
    Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: June 14, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiaki Ohashi, Yoshihiko Norimine, Tamaki Hoshikawa, Yu Yoshida, Yoshihisa Kobayashi, Nobuhiro Sato, Koji Hagiwara, Nobuaki Sato, Shinsuke Hirota, Takaaki Harada, Hikaru Yoshimura
  • Drug combinations for reducing cell viability and/or cell proliferation
    Patent number: 11357769
    Abstract: Provided herein is a combination of agents for reducing cell viability and/or cell proliferation. The combination comprises an FGFR4 inhibitor and an EGFR inhibitor.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 14, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Anand Selvaraj, Peter Smith
  • Splicing modulator antibody-drug conjugates and methods of use
    Patent number: 11352348
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: June 7, 2022
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
  • Compounds for the treatment of cancer
    Patent number: 11339188
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: May 24, 2022
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Method for producing an active hepatocyte growth factor (HGF)
    Patent number: 11325960
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Monoclonal antibody against APOA4, immunological measurement method, and kit for measurement
    Patent number: 11327078
    Abstract: The present invention provides an anti-APOA4 monoclonal antibody or an antibody fragment thereof capable of accurately measuring apolipoprotein A-IV (APOA4) in a specimen, a measurement method for immunologically measuring APOA4 using the antibody or the antibody fragment thereof, and a kit for measuring APOA4 containing the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoko Ida, Takashi Obara, Emiko Yumoto
  • Lyophilized formulation of HGF
    Patent number: 11324805
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Hydrochloride salt of 2-((3R,4S)-1-(5-(4-chloro-3,5-difluorophenyl)-7-((2-fluoro-6-methylphenyl)(methyl)amino)pyrazolo[1,5-a]pyrimidine-2-carbonyl)-3-methoxypiperidin-4-yl) acetic acid and crystals thereof
    Patent number: 11312720
    Abstract: A salt of the compound represented by formula (1) and crystals thereof having the potential to be used as drug substances for pharmaceutical products.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 26, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Taro Yamashita
  • Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
    Patent number: 11311530
    Abstract: Provided is a therapeutic agent for Lewy body disease comprising (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 26, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Yukio Ishikawa
  • Pharmaceutical Composition for Treating Tumor
    Publication number: 20220117933
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Applicants: Eisai R&D Management Co., Ltd., Ono Pharmaceutical Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • METHOD FOR SYNTHESIS OF DIAZABICYCLO[6.2.0]DECANE RELATED COMPOUNDS
    Publication number: 20220112207
    Abstract: A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclization results with the formation of diazobicyclo[6.2.0]decane related compounds.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 14, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. FANG, Branko MITASEV, Jiong YANG
  • ANTI-BCMA ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20220081486
    Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
    Type: Application
    Filed: June 4, 2021
    Publication date: March 17, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Ryan Henry, Thiwanka Samarakoon, Nathan Fishkin, Ping Zhu, Ermira Pazolli, James Palacino, Juan C. Almagro
  • Pentacyclic heterocycles
    Patent number: 11267821
    Abstract: The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 8, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiaki Ohashi, Yoshihiko Norimine, Tamaki Hoshikawa, Yu Yoshida, Yoshihisa Kobayashi, Nobuhiro Sato, Koji Hagiwara, Nobuaki Sato, Shinsuke Hirota, Takaaki Harada, Hikaru Yoshimura
  • High-Purity Quinoline Derivative and Method for Manufacturing Same
    Publication number: 20220048862
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Application
    Filed: October 27, 2021
    Publication date: February 17, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • TREATMENT OF HEPATOCELLULAR CARCINOMA
    Publication number: 20220040168
    Abstract: This disclosure provides methods for treating a hepatocellular carcinoma (e.g., unresectable HCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Also encompassed by the disclosure are dosage regimens described herein of lenvatinib or a pharmaceutically acceptable salt thereof for use in treating hepatocellular carcinoma (e.g., unresectable hepatocellular carcinoma) according to any of the methods described herein. Particularly useful dosages and dose modifications upon the occurrence of an adverse event or events are also disclosed.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 10, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Toshiyuki Tamai
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR FOR TREATING CANCER
    Publication number: 20220023285
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Application
    Filed: October 15, 2021
    Publication date: January 27, 2022
    Applicants: MERCK SHARP & DOHME CORP., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Andrew Evan DENKER, Yu KATO, Kimiyo TABATA, Yusaku HORI
  • Aqueous Based Pharmaceutical Formulations of 1,2-Dihydropyridine Compounds
    Publication number: 20220023275
    Abstract: An aqueous pharmaceutical formulation of a solubilizing agent with a pyridone compound that is useful as an inhibitor to non-NMDA receptors, particularly to the AMPA receptor is disclosed herein. In some embodiments the pyridone compound is supersaturated in aqueous solution at pH between 6 and 8. The formulations are particularly useful as intravenous injections.
    Type: Application
    Filed: December 16, 2019
    Publication date: January 27, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Geoffrey S. HIRD, Ganesh S.P. BOMMAREDDY, Anjali JOSHI, Ph.D., James MCSHANE
  • SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE
    Publication number: 20220017517
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 20, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yu YOSHIDA, Yoichi KITA, Makoto KOTAKE, Keiichi SORIMACHI, Toshiyuki OHFUSA, Takafumi MOTOKI, Taro ASABA
  • Therapeutic agent for hepatocellular carcinoma
    Patent number: 11219619
    Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: January 11, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsumi Yamaguchi, Hajime Shimizu, Satoshi Goda, Saori Miyano
  • Modified nucleic acid monomer compound and oligonucleic acid analog
    Patent number: 11208429
    Abstract: The present invention provides a modified nucleic acid monomer compound having a specific backbone such as 2-ethylglycerol or methoxymethyl-1,3-propanediol backbone instead of a ribose or deoxyribose backbone of a nucleoside, and an oligonucleic acid analogue containing the monomer compound as at least one of building blocks. The oligonucleic acid analogue containing the nucleic acid monomer compound of the present invention allows provision of an oligonucleic acid analogue having excellent biological stability and/or target gene silencing activity.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshinori Takahashi, Yuta Suzuki